文献速递消化系统肿瘤

循环甲基化SEPT9用于肝硬化患者肝细胞癌检测

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.
PubMed 文献 · JAMA Oncol · 2026-01-01

这项前瞻性横断面诊断准确性研究在2个法国学术中心纳入574例接受常规监测的肝硬化患者,评估血浆甲基化SEPT9联合AFP检测HCC的性能。

要点

  • 甲基化SEPT9单独检测HCC的AUROC优于AFP(0.79 vs 0.71)。
  • 联合策略(任一项阳性)敏感性87.8%,可挽回AFP漏诊的78% HCC。
  • BCLC 0-A期联合策略敏感性74.5%,显著高于AFP的23.5%。

核心结论

  • 在肝硬化监测人群中,甲基化SEPT9联合AFP可显著提高HCC检测率,尤其对可根治的早期疾病。
  • 尚需前瞻性研究验证检测改善能否转化为生存获益。

研究设计与样本

  • 前瞻性、横断面诊断准确性研究,2018年2月至2024年10月在2个法国学术中心纳入574例接受超声和AFP常规监测的肝硬化患者。
  • HCC按国际指南诊断并经集中影像学复核,对甲基化SEPT9结果设盲。

主要发现

  • 574例中118例患HCC,其中51例(43.2%)为BCLC 0-A期。
  • Tier 1a(至少单阳性甲基化SEPT9或AFP>20 ng/mL)敏感性87.8%(95%CI 81.6-93.5),阴性似然比0.2(95%CI 0.1-0.3)。
  • AFP漏诊的64例HCC中,Tier 1a挽回50例(78%)。
  • BCLC 0-A期Tier 1a敏感性74.5%(95%CI 62.2-86.5),AFP为23.5%(95%CI 12.5-35.8),提高3.2倍。

关键数值与推荐

  • AFP阈值采用20 ng/mL。
  • 甲基化SEPT9按3个独立血浆等份的阳性重复数分为单阳性、双阳性或三阳性。
  • Tier 1(析取逻辑,最大化敏感性):至少单阳性甲基化SEPT9或AFP>20 ng/mL。
  • Tier 2(合取逻辑,最大化特异性):三阳性甲基化SEPT9且AFP>20 ng/mL。

临床怎么用

  • 在肝硬化HCC监测中,可考虑将血浆甲基化SEPT9与AFP联合使用以提高检出敏感性。
  • 联合策略有助于发现AFP阴性的早期HCC,尤其是BCLC 0-A期可根治病变。
  • 高特异性联合模式(三阳性且AFP升高)可用于辅助确认诊断。

局限性

  • 研究为横断面设计,未评估检测改善是否转化为生存获益。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis remains suboptimal, with inadequate early-stage detection. α-Fetoprotein (AFP) demonstrates insufficient sensitivity. Circulating methylated septin 9 (SEPT9) has shown diagnostic promise. OBJECTIVE: To determine whether methylated SEPT9 improves detection of HCC when combined with AFP in patients with cirrhosis undergoing surveillance. DESIGN, SETTING, AND PARTICIPANTS: In this prospective, cross-sectional, diagnostic accuracy study, patients with cirrhosis undergoing routine HCC surveillance with ultrasonography and AFP were enrolled at 2 French academic centers from February 2018 through October 2024. HCC was diagnosed per international guidelines with centralized radiologic review, blinded to methylated SEPT9 results. Data were analyzed from October 2025 to January 2026. EXPOSURES: Plasma methylated SEPT9 was analyzed from 3 independent plasma aliquots and classified by number of positive replicates (single-positive, double-positive, or triple-positive). Serum AFP was evaluated at a threshold of 20 ng/mL. Biomarkers were evaluated individually and in combination using disjunction logic (tier 1; maximizing sensitivity) or conjunction logic (tier 2; maximizing specificity). MAIN OUTCOMES AND MEASURES: The primary outcome was the presence of HCC at enrollment. The primary end point was comparison of the area under the receiver operating characteristic curve (AUROC) between methylated SEPT9 and AFP. Secondary end points included diagnostic performance stratified by Barcelona Clinic Liver Cancer (BCLC) stage. RESULTS: Among 574 participants, 414 (72.1%) were male, and the median (IQR) age was 63 (57-70) years. A total of 118 had HCC, including 51 (43.2%) with BCLC stage 0-A. Methylated SEPT9 outperformed AFP (AUROC: 0.79 [95% CI, 0.74-0.84] vs 0.71 [95% CI, 0.66-0.76], respectively; P = .002; posterior probability of superiority >99.8%). Tier 1a (at least single-positive methylated SEPT9 or AFP >20 ng/mL) achieved 87.8% (95% CI, 81.6-93.5) sensitivity and a negative likelihood ratio of 0.2 (95% CI, 0.1-0.3). Among 64 HCC cases missed by AFP, tier 1a recovered 50 (78%). For BCLC 0-A disease, tier 1a sensitivity was 74.5% (95% CI, 62.2-86.5) vs 23.5% (95% CI, 12.5-35.8) for AFP, 3.2-fold increase. Tier 2 (triple-positive methylated SEPT9 and AFP >20 ng/mL) achieved 99.6% (95% CI, 98.9-100) specificity, a positive likelihood ratio of 76.0 (95% CI, 26.9-181.0), and a diagnostic odds ratio of 112.1 (95% CI, 37.8-294.7). CONCLUSIONS AND RELEVANCE: In this diagnostic study, combining methylated SEPT9 with AFP substantially improved HCC detection in patients with cirrhosis, particularly for early-stage disease amenable to curative treatment. Prospective studies are needed to determine whether improved detection translates into survival benefit.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Oussalah A, Silva Rodriguez M, Conroy G, et al. Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis. JAMA Oncol. 2026. PMID: 42390849. doi:10.1001/jamaoncol.2026.2157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。